Since VEGF is considered to be the most important regulator of tumor angiogenesis, antibodies against VEGF and VEGFR, as well as small molecule tyrosine kinase inhibitors (TKIs) that can inhibit VEGF receptor signaling, are the main types of antiangiogenic therapy [60]. Here, VEGFA is linked to neoplasm.